Compare APWC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | FEMY |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 37.2M |
| IPO Year | 1997 | 2021 |
| Metric | APWC | FEMY |
|---|---|---|
| Price | $1.68 | $0.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 13.6K | ★ 934.7K |
| Earning Date | 03-30-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $492,001,000.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $12.45 | ★ N/A |
| Revenue Growth | 5.10 | ★ 63.53 |
| 52 Week Low | $1.45 | $0.31 |
| 52 Week High | $2.34 | $1.80 |
| Indicator | APWC | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 38.03 |
| Support Level | $1.64 | $0.47 |
| Resistance Level | $1.71 | $0.53 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 45.15 | 21.02 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.